Protekt Therapeutics News
5 articles
החברה שמצאה מנגנון חדש שעשוי לעכב אלצהיימר
Israeli company ProteKt Therapeutics is developing a new treatment for Alzheimers disease based on a mechanism called PKR. The company has developed a drug that inhibits the activity of PKR, which is released in the body during stress, and can cause a reduction in protein production in cells. The company has raised $3.6 million in a recent funding round from investors including Fonds de Solidarite and Bukwang Pharmaceutical, bringing its total funding to over $7 million.
Investment
Israeli startup hopes to battle Alzheimer's with enzyme-busting drug
Israeli startup ProteKt Therapeutics is developing a drug to treat early stages of Alzheimer’s by targeting an enzyme. The company has raised $3.6 million in funding from investors including Quebec’s Fonds de solidarité FTQ fund and Korean pharma firm Bukwang Pharmaceutical. ProteKt has identified a series of 150 small synthetic compounds that could help inhibit the enzyme and has shown their potential to improve cognition in lab tests. The funding will be used to further develop and improve the most effective molecule and conduct animal testing. ProteKt aims to prove that the compound can enter the brain and plans to undertake clinical trials in the future.
Investment
Israeli co ProteKt Therapeutics raises $3.6m
ProteKt Therapeutics, an Israeli biotech company, has signed a binding agreement for a $3.6 million equity financing round. The financing will be used to select a lead drug candidate molecule and validate its neurotherapeutic effects in vivo. The company also plans to initiate the clinical development of a related diagnostic assay for patient selection and treatment personalization. The funding will enable ProteKt Therapeutics to continue the development of novel therapies for neurodegenerative diseases, such as Alzheimers disease. The company aims to adopt a precision medicine approach and develop a patient selection diagnostic assay to increase the likelihood of effective treatment. The equity financing round was co-led by Fonds de Solidarité FTQ and Bukwang Pharmaceutical, along with existing investors FutuRx, OrbiMed, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., and RM Global Partners (RMGP) BioPharma Investment Fund.
Investment
RM Global to invest $30m in FutuRx biotech startups
US-based international investment bank RM Global is establishing a new venture capital fund that has already closed its first financing round of $30 million and will soon embark on a second financing round. The fund will invest exclusively in companies operating in Israels FutuRx incubator in Ness Ziona near Rehovot. The fund has raised money from financial and strategic investors, and hopes to raise additional tens of millions of dollars.
InvestmentPartners
Haifa team IDs activity of proteins linked to memory loss
A study by University of Haifa scientists has identified brain proteins associated with memory impairments in Alzheimers disease. The study also found that repairing this activity leads to an improvement in memory. The researchers hope to develop a drug that can delay the onset of cognitive symptoms. The study was published in the Journal of Neuroscience.
InvestmentPartners
